Q2 EPS Estimate for Capricor Therapeutics Lowered by Analyst

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Capricor Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($0.61) per share for the quarter, down from their prior forecast of ($0.60). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.43) EPS and FY2027 earnings at ($2.57) EPS.

Several other brokerages have also recently commented on CAPR. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. B. Riley Financial increased their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $48.36.

Capricor Therapeutics Trading Down 1.7%

Shares of NASDAQ:CAPR opened at $29.81 on Friday. Capricor Therapeutics has a 1-year low of $4.30 and a 1-year high of $40.37. The stock has a market capitalization of $1.72 billion, a P/E ratio of -12.85 and a beta of 0.48. The business has a 50-day moving average price of $31.79 and a two-hundred day moving average price of $24.20.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04).

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the company. Sei Investments Co. boosted its position in shares of Capricor Therapeutics by 41.2% during the first quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company’s stock worth $541,000 after purchasing an additional 5,195 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Capricor Therapeutics in the 1st quarter valued at $5,397,000. KBC Group NV bought a new stake in shares of Capricor Therapeutics in the 1st quarter valued at $44,000. Swiss National Bank acquired a new stake in Capricor Therapeutics during the 1st quarter worth $2,943,000. Finally, Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 10.4% during the first quarter. Bank of New York Mellon Corp now owns 130,730 shares of the biotechnology company’s stock worth $3,974,000 after acquiring an additional 12,366 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Capricor Therapeutics

In related news, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. The trade was a 75.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 172,529 shares of company stock worth $5,302,440. Company insiders own 9.20% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.